Trial Profile

Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emvododstat (Primary)
Indications Respiratory tract disorders; SARS-CoV-2 acute respiratory disease
Focus Registrational; Therapeutic Use
Acronyms FITE19
Sponsors PTC Therapeutics

Most Recent Events

11 Feb 2024 This trial has been Discontinued in Portugal, according to European Clinical Trials Database record.
09 Jan 2023 Status changed from recruiting to completed, according to a PTC Therapeutics media release.
08 Sep 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com